or Try an Advanced Search...

    Technical Analysis for KZIA - Kazia Therapeutics Limited

    Grade Last Price % Change Price Change
    C 5.70 1.65% 0.09
    KZIA closed down 1.75 percent on Wednesday, November 20, 2024, on 25 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Up
    Historical KZIA trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 1.65%
    Wide Bands Range Expansion 1.65%
    Crossed Above 20 DMA Bullish -0.13%
    New Uptrend Bullish -0.13%
    Wide Bands Range Expansion -0.13%
    Crossed Above 50 DMA Bullish 12.25%
    Stochastic Reached Oversold Weakness 12.25%
    Wide Bands Range Expansion 12.25%
    Lower Bollinger Band Touch Weakness 12.25%
    Oversold Stochastic Weakness 12.25%
    Older End-of-Day Signals for KZIA ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 20 DMA about 1 hour ago
    60 Minute Opening Range Breakout about 1 hour ago
    Rose Above 10 DMA about 1 hour ago
    Up 3% about 1 hour ago
    Up 2% about 1 hour ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    KZIA Chart by TradingView
    Basic chart:

    Profile

    Kazia Therapeutics Limited Description

    Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Cancer Treatment ATM Chemotherapy Ovarian Cancer Blastoma Cancer Cell Glioma Neuroblastoma Cytoskeleton Diffuse Intrinsic Pontine Glioma Novogen Pharmaceutical Research

    Is KZIA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 4 Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme
    Oct 16 Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing
    Oct 2 Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Societ...
    Sep 12 Kazia Therapeutics enters into licensing agreement with QIMR Berghofer
    Sep 12 KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER
    Jul 25 Biotech Stock Laboratory: Try a Small Experiment With Kazia Therapeutics
    Jul 12 Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
    Jul 12 From Pennies to Dollars: 3 Sub-$5 Stocks Set to Explode Higher
    Jul 11 Kazia Therapeutics stocks soar following Phase II/III win
    Jul 10 Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    See more KZIA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.8
    52 Week Low 1.866
    Average Volume 170,182
    200-Day Moving Average 3.64
    50-Day Moving Average 4.68
    20-Day Moving Average 5.65
    10-Day Moving Average 5.67
    Average True Range 0.76
    RSI (14) 50.98
    ADX 27.47
    +DI 25.36
    -DI 23.38
    Chandelier Exit (Long, 3 ATRs) 5.53
    Chandelier Exit (Short, 3 ATRs) 6.58
    Upper Bollinger Bands 6.80
    Lower Bollinger Band 4.49
    Percent B (%b) 0.48
    BandWidth 40.83
    MACD Line 0.20
    MACD Signal Line 0.32
    MACD Histogram -0.1252
    Fundamentals Value
    Market Cap 147.89 Million
    Num Shares 26.4 Million
    EPS -0.73
    Price-to-Earnings (P/E) Ratio -7.68
    Price-to-Sales 12881.51
    Price-to-Book 0.96
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 6.38
    Resistance 3 (R3) 6.42 6.22 6.25
    Resistance 2 (R2) 6.22 6.02 6.19 6.20
    Resistance 1 (R1) 5.91 5.90 5.81 5.87 6.16
    Pivot Point 5.71 5.71 5.66 5.68 5.71
    Support 1 (S1) 5.40 5.51 5.30 5.36 5.06
    Support 2 (S2) 5.20 5.39 5.17 5.02
    Support 3 (S3) 4.89 5.20 4.97
    Support 4 (S4) 4.85